Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geldart

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
European Urology Focus|February 11, 2019
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted TherapyPeter E Hall, Scott T C Shepherd, Janet Brown, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2017
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-lossSimon J Crabb, Karen Martin, Julia Abab, et al.
Human Molecular Genetics|December 6, 2011
Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIPXiaobo Zhou, Rebecca M Baron, Megan Hardin, et al.
Future Oncology (London, England)|January 19, 2023
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS dataParneet Cheema, Byoung Chul Cho, Helano Freitas, et al.
Lung Cancer (Amsterdam, Netherlands)|October 24, 2025
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort studyIgor Gomez-Randulfe, Federico Monaca, Ornella Cantale, et al.
JTO Clinical and Research Reports|January 13, 2025
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World StudyLaura Moliner, Núria Zellweger, Sabine Schmid, et al.
JCO Precision Oncology|March 21, 2024
Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung CancerPetros Christopoulos, Michal Harel, Kimberly McGregor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2022
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)Johnathan K Joffe, Fay H Cafferty, Laura Murphy, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
European Urology Focus|February 11, 2019
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted TherapyPeter E Hall, Scott T C Shepherd, Janet Brown, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2017
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-lossSimon J Crabb, Karen Martin, Julia Abab, et al.
Human Molecular Genetics|December 6, 2011
Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIPXiaobo Zhou, Rebecca M Baron, Megan Hardin, et al.
Future Oncology (London, England)|January 19, 2023
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS dataParneet Cheema, Byoung Chul Cho, Helano Freitas, et al.
Lung Cancer (Amsterdam, Netherlands)|October 24, 2025
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort studyIgor Gomez-Randulfe, Federico Monaca, Ornella Cantale, et al.
JTO Clinical and Research Reports|January 13, 2025
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World StudyLaura Moliner, Núria Zellweger, Sabine Schmid, et al.
JCO Precision Oncology|March 21, 2024
Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung CancerPetros Christopoulos, Michal Harel, Kimberly McGregor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2022
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)Johnathan K Joffe, Fay H Cafferty, Laura Murphy, et al.
Pageof 10